Cargando…

Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome

The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ionin, Valery A., Baranova, Elena I., Zaslavskaya, Ekaterina L., Petrishcheva, Elena Yu., Morozov, Aleksandr N., Shlyakhto, Evgeny V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461109/
https://www.ncbi.nlm.nih.gov/pubmed/32784491
http://dx.doi.org/10.3390/ijms21165689
_version_ 1783576716566855680
author Ionin, Valery A.
Baranova, Elena I.
Zaslavskaya, Ekaterina L.
Petrishcheva, Elena Yu.
Morozov, Aleksandr N.
Shlyakhto, Evgeny V.
author_facet Ionin, Valery A.
Baranova, Elena I.
Zaslavskaya, Ekaterina L.
Petrishcheva, Elena Yu.
Morozov, Aleksandr N.
Shlyakhto, Evgeny V.
author_sort Ionin, Valery A.
collection PubMed
description The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study: MS patients (n = 337), 176 of whom had AF, 72 patients with AF without MS and 71 healthy subjects. Galectin-3, PINP and PIIINP blood concentrations and metabolic parameters were compared with the severity of left atrium fibrosis, measured by CARTO3. Galectin-3 in AF and MS patients is higher than in MS without AF and in healthy subjects (10.3 (4.8–15.4), 5.1 (4.3–8.8), 3.2 (2.4–4.2) ng/mL, p < 0.0001). Galectin-3 serum concentration in AF patients with MS is higher than in patients without MS: 10.3 (4.8–15.4), 6.8 (5.2–8.1) ng/mL, p = 0.0001. PINP and PIIINP concentration were higher in patients with AF and MS than in MS without AF: 3499.1 (2299.2–4567.3), 2130.9 (1425.3–2861.8) pg/mL, p < 0.0001, 94.9 (64.8–123.5), 57.6 (40.5–86.9) ng/mL, p < 0.0001. Galectin-3 correlates with PINP (r = 0.496, p < 0.001) and PIIINP concentration (r = 0.451, p < 0.0001). The correlation between galectin-3, PINP and the severity of left atrium fibrosis was found (r = 0.410, p < 0.001; r = 0.623, p < 0.001). Galectin-3 higher than 12.6 ng/mL increased the risk of AF more than five-fold. High galectin-3, PINP and PIIINP concentrations were associated with heart remodeling in MS patients and increased the risk of AF.
format Online
Article
Text
id pubmed-7461109
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74611092020-09-14 Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome Ionin, Valery A. Baranova, Elena I. Zaslavskaya, Ekaterina L. Petrishcheva, Elena Yu. Morozov, Aleksandr N. Shlyakhto, Evgeny V. Int J Mol Sci Article The aim of this study was to determine the concentration of galectin-3, PINP and PIIINP in patients with metabolic syndrome (MS) and atrial fibrillation (AF) with an assessment of the relationship with severity of left atrium fibrosis. A total of 480 subjects were included in the case-control study: MS patients (n = 337), 176 of whom had AF, 72 patients with AF without MS and 71 healthy subjects. Galectin-3, PINP and PIIINP blood concentrations and metabolic parameters were compared with the severity of left atrium fibrosis, measured by CARTO3. Galectin-3 in AF and MS patients is higher than in MS without AF and in healthy subjects (10.3 (4.8–15.4), 5.1 (4.3–8.8), 3.2 (2.4–4.2) ng/mL, p < 0.0001). Galectin-3 serum concentration in AF patients with MS is higher than in patients without MS: 10.3 (4.8–15.4), 6.8 (5.2–8.1) ng/mL, p = 0.0001. PINP and PIIINP concentration were higher in patients with AF and MS than in MS without AF: 3499.1 (2299.2–4567.3), 2130.9 (1425.3–2861.8) pg/mL, p < 0.0001, 94.9 (64.8–123.5), 57.6 (40.5–86.9) ng/mL, p < 0.0001. Galectin-3 correlates with PINP (r = 0.496, p < 0.001) and PIIINP concentration (r = 0.451, p < 0.0001). The correlation between galectin-3, PINP and the severity of left atrium fibrosis was found (r = 0.410, p < 0.001; r = 0.623, p < 0.001). Galectin-3 higher than 12.6 ng/mL increased the risk of AF more than five-fold. High galectin-3, PINP and PIIINP concentrations were associated with heart remodeling in MS patients and increased the risk of AF. MDPI 2020-08-08 /pmc/articles/PMC7461109/ /pubmed/32784491 http://dx.doi.org/10.3390/ijms21165689 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ionin, Valery A.
Baranova, Elena I.
Zaslavskaya, Ekaterina L.
Petrishcheva, Elena Yu.
Morozov, Aleksandr N.
Shlyakhto, Evgeny V.
Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title_full Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title_fullStr Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title_full_unstemmed Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title_short Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome
title_sort galectin-3, n-terminal propeptides of type i and iii procollagen in patients with atrial fibrillation and metabolic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461109/
https://www.ncbi.nlm.nih.gov/pubmed/32784491
http://dx.doi.org/10.3390/ijms21165689
work_keys_str_mv AT ioninvalerya galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome
AT baranovaelenai galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome
AT zaslavskayaekaterinal galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome
AT petrishchevaelenayu galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome
AT morozovaleksandrn galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome
AT shlyakhtoevgenyv galectin3nterminalpropeptidesoftypeiandiiiprocollageninpatientswithatrialfibrillationandmetabolicsyndrome